Objectives: a) To evaluate the relationship between hyperbilirubinemia and other parameters such as HIV infection stage, coinfection with hepatotropic viruses and concomitant antiretroviral treatments in subjects treated with indinavir (IDV)-containing HAART; b) To describe hyperbilirubinemia kinetics in the same cohort. Materials and methods: We evaluated retrospectively a cohort of 104 HIV+ individuals treated with a IDV-containing HAART for at least 12 mos. Hyperbilirubinemia was defined as a plasmatic total bilirubin level above 2.00 mg/dL. Results: Out of 104 pts., 37 (35.6%) resulted hyperbilirubinemic; 21/37 (56.7%) belonged to CDC '93 stage A, 16/37 (43.3%) to stages B and C. HCV coinfection was demonstrated in 18/37 (48.6%). Hyperbilirubinemia arose within the first trimester of treatment in 31/37 pts. (83.7%) and peaked within the second trimester in 21/37 (56.7%). Sixteen pts. were being treated with AZT+ 3TC (43.2%), 11 with d4T+ 3TC (29.8%), 8 with d4T+ddI (21.6%) and 2 with AZT+ddI (5.4%). An elevation of aminotransferases was also documented within the first yr. of treatment in 27/37 pts. (73%).
|Translated title of the contribution||Kinetics of hyperbilirubinemia associated with indinavir: A case- control study|
|Number of pages||4|
|Journal||Giornale Italiano di Malattie Infettive|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Microbiology (medical)